Project 05: Translational Therapeutics (TT)

项目05：转化疗法（TT）

• 批准号: 10089997
• 负责人: DAVID P. CARBONE
• 金额: $ 6.16万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-12 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10089997
• 关键词: Abbreviations; Adult; Award; Basic Science; Biological; Biometry; Cancer Biology; Cancer Center Support Grant; Cancer Control; Cancer Etiology; Catchment Area; Cessation of life; Chemoprevention; Childhood; Clinical; Clinical Treatment; Clinical Trials; Collaborations; Colorectal Cancer; Comparative Pathology; Comprehensive Cancer Center; Decision Making; Diagnosis; Direct Costs; Discipline; Disease; Doctor of Philosophy; Exhibits; Flow Cytometry; Funding; Future; Genomics; Glioblastoma; Goals; Grant; Growth; Head Cancer; Immune checkpoint inhibitor; Immune system; Immunogenomics; Immunooncology; Immunotherapeutic agent; Institutes; Intervention; Intramural Research Program; Journals; Longevity; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of thyroid; Medicine; Microscopy; Molecular; Molecular Biology; Molecular Carcinogenesis; Morbidity - disease rate; NCI Center for Cancer Research; National Cancer Institute; National Comprehensive Cancer Network; Neck Cancer; Non-Small-Cell Lung Carcinoma; Ohio; Oncology; Outcome; Patients; Pediatric Hospitals; Peer Review; Peer Review Grants; Pharmaceutical Chemistry; Pharmacy facility; Physicians; Prognosis; Proteomics; Publications; Publishing; Research; Research Personnel; Research Priority; Resistance; Resource Sharing; Scientist; Services; Signal Pathway; Solid Neoplasm; The Cancer Genome Atlas; Therapeutic; Tissues; Training; Translating; Translational Research; United States National Institutes of Health; Universities; Validation; Veterinary Medicine; animal imaging; biomedical informatics; cancer care; cancer cell; college; colon cancer prevention; digital imaging; drug development; host neoplasm interaction; improved; innovation; interest; investigator-initiated trial; leukemia; malignant breast neoplasm; meetings; member; mortality; multidisciplinary; pathology imaging; preclinical study; prognostic; programs; recruit; sarcoma; small molecule; therapeutic target; treatment response; tumor; tumor heterogeneity; tumor progression

PROJECT SUMMARY – TRANSLATIONAL THERAPEUTICS (TT) The Translational Therapeutics (TT) Program at The Ohio State University Comprehensive Cancer Center (OSUCCC), co-led by David Carbone, MD, PhD, Blake Peterson, PhD, and Elaine Mardis, PhD, unites an outstanding team of 79 basic, translational and/or clinical researchers from 18 departments within The Ohio State University (OSU) Colleges of Medicine, Pharmacy, and Veterinary Medicine and Nationwide Children’s Hospital (NCH). The goal of the TT program is to translate advances in solid tumor molecular biology and promising preclinical studies into innovative clinical trials to improve the state of the art in the diagnosis and treatment of solid tumors. Solid tumors are by far the major causes of cancer death in our catchment area (the state of Ohio), dominated by diseases of special interest in this program, including lung, breast, colorectal, head and neck, thyroid, and gynecologic cancers. As a result of existing expertise and collaborative scientific efforts, as well as focused recruitments across a spectrum of disciplines, the TT program exhibits strength in basic and translational research in lung cancer, gastrointestinal malignancies, breast cancer, sarcoma, and glioblastoma, as well as newly enhanced capabilities in drug development. The Specific Aims of the TT program are to: 1) identify and therapeutically target alterations in solid tumor proliferation and survival signaling pathways; 2) identify tumor-host interactions and target them via small molecule and immunotherapeutic approaches; and 3) develop and improve upon approaches for determining prognosis, selecting appropriate therapies, and evaluating the response to treatment. During the current funding cycle, the TT Program successfully recruited 28 solid tumor clinicians, basic scientists, and physician-scientists. In addition, TT investigators produced 1130 peer-reviewed publications; 178 of these were published in high impact (≥10) journals, 16% resulted from intra- programmatic collaborations, and 31% from inter-programmatic collaborations; 74% were multi-institutional; a total of 86% were collaborative publications. TT members collaborated on programmatic grant submissions and were awarded one NCI P01, two U01s, and two UG1s, as well as two T32 training grants. The TT Program has $9.2M in current annual direct costs from peer-reviewed grants, $6.6M (71%) of which is from the NCI. The TT Program is well-integrated with the clinical teams via participation in the multidisciplinary Disease Specific Research Groups (DSRG) and organizes Pan-Disease Investigator-Initiated Trial meetings to catalyze interactions between DSRGs. As such, there were 4,070 accruals to interventional clinical trials during the last funding cycle, of which 3,351 (82%) were therapeutic, including 1,144 (28%) investigator-initiated trials. Future directions focused on the OSUCCC research priorities and cancers relevant to our catchment area and growth in cellular and checkpoint inhibitor research (adult and pediatric), immunogenomics, tumor resistance and tumor heterogeneity and small molecule drug development.

项目摘要 - 转化治疗（TT） 俄亥俄州立大学综合癌症中心的转化治疗学（TT）计划 （OSUCCC），由医学博士David Carbone，博士，Blake Peterson博士和Elaine Mardis，博士 来自俄亥俄州18个部门的79个基本，翻译和/或临床研究人员的杰出团队 州立大学（OSU）医学，药房和兽医学院以及全国儿童 医院（NCH）。 对创新属性的有希望的临床前研究，以改善诊断和 实体瘤的治疗是迄今为止我们集水区癌症死亡的主要原因（ 俄亥俄州），以该计划特别感兴趣的疾病为主导，包括肺部，酥脆，结直肠，头部 颈部，甲状腺和妇科癌症。 除了跨学科范围的集中招聘外，TT计划还表现出强度的基础和 肺癌，胃肠道恶性肿瘤，乳腺癌，肉瘤和胶质母细胞瘤的转化研究， 以及新近增强的药物开发能力。 识别和治疗靶向实体肿瘤的刺激信号传导途径的变化； 识别肿瘤宿主相互作用，并通过小分子和免疫治疗方法靶向； 开发和改进确定预后的方法，选择适当的疗法和饮食 评估当前资金周期，TT计划成功招募 28个实体临床医生，基本科学家和医师科学家。 同行评审的出版物； 计划合作，实习生合作的31％； 总共有86％的合作出版物。 被授予一个NCI P01，两个U01和两个UG1，以及两个T32培训赠款。 从同行评审的当前年度直接成本为920万美元，其中660万美元（71％）来自NCI 通过参与多学科疾病特定的临床团队，计划与临床团队有充分的整合 研究小组（DSRG）并组织了Pan-Disease研究者发起的试验会议，以催化 DSRG之间的相互作用。 筹资周期，其中3,351（82％）是治疗性的，其中包括1,144（28％）研究者的试验。 针对OSUCCCH优先事项的方向和与我们的集水区和增长有关的癌症 在细胞和检查点抑制剂研究（成人和小儿）中，免疫基因组学，肿瘤和肿瘤 异质性和小分子药物开发。